Disturbed endothelial cell signaling in tumor progression and therapy resistance

Fischer, Andreas; Alsina-Sanchis, Elisenda

doi:10.1016/j.ceb.2023.102287

Cited by 5 publications

(2 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a result, vascularization and tumor growth are stimulated, and a violation of the process of effector extravasation of T cells is observed. Tumor endothelial cells contribute to the accumulation of Tregs and enhance negative regulators of T cell activation (PD-L1, PD-L2, and IL) (Fischer & Alsina-Sanchis, 2024).…”

Section: Mechanisms Of Resistance Associated With the Tumor Microenvi...mentioning

confidence: 99%

Biological mechanisms of resistance to immune checkpoint inhibitors and overcoming this resistance: Challenges in medical oncology

Moskalenko

2024

Regul. Mech. Biosyst.

View full text Add to dashboard Cite

Immune checkpoint inhibitors have opened up new possibilities in clinical oncology. Monoclonal antibodies have shown their high clinical efficiency. They block CTLA-4, PD-1, and PD-L1 receptors and activate the immune response. Many patients have stable and even complete responses. However, some patients have primary or acquired resistance. Therefore, the treatment results in this category of patients are not predictable. Mechanisms of resistance to immune checkpoint inhibitors have not been definitively studied. Many theories try to explain the mechanisms of this phenomenon. Our study aimed to structure and combine the data into groups depending on the etiological factor that reduces the immune response. In addition, based on understanding the mechanisms of resistance and the results of recent clinical studies, we aimed to identify the main ways to overcome it. Therefore, mechanisms that lead to resistance may be associated with tumor properties, tumor microenvironment, or patient characteristics. Tumor properties that reduce the immune response include a) low tumor mutation burden and loss of tumor neoantigens, b) changes in the processing or presentation of neoantigens, and c) changes in signaling pathways of tumor development and epigenetic modifications in genes. The tumor microenvironment is represented by stromal and immune cells, extracellular matrix, cytokines, and blood vessels. Each structure can enhance or reduce the immune response and contribute to the acquired resistance to immune checkpoint inhibitors. The effectiveness of the treatment depends not only on the cells in the tumor microenvironment but also on the metabolic background. In addition, the basic characteristics of the patient ( gender, gut microbiota, HLA-I genotype) can modify the immune response. Based on knowledge about the mechanisms of resistance to immune checkpoint inhibitors, several therapeutic strategies aimed at activating antitumor activity have been evaluated. All of them are based on combining immune checkpoint inhibitors with other drugs. One of the most common options is a combination of PD-1/PD-L1 and CTLA-4 inhibitors. Alternative immune checkpoints are TIM-3, LAG-3, TIGIT and VISTA. Combining immunotherapy with chemotherapy, targeted therapy, neoangiogenesis inhibitors, epigenetic modifiers, PARP or TGF-β inhibitors enhances antitumor response by preventing depletion of effector T cells, enhancing T cell infiltration in the tumor, changes on the tumor microenvironment, and decreasing the accumulation of immunosuppressive cells. This review explores the biological mechanisms of resistance and potential ways of solving this problem.

show abstract

Section: Mechanisms Of Resistance Associated With the Tumor Microenvi...mentioning

confidence: 99%

Biological mechanisms of resistance to immune checkpoint inhibitors and overcoming this resistance: Challenges in medical oncology

Moskalenko

2024

Regul. Mech. Biosyst.

View full text Add to dashboard Cite

show abstract

“…161 Therefore, targeting the growth of tumour endothelial cells and reducing VEGF expression holds promise as an effective approach to inhibit GBM progression. 162 For instance, the use of bevacizumab, which targets VEGF, has been widely employed in clinical tumour therapy to impact angiogenesis. 163 However, systemic administration of anti-VEGF agents has shown limited clinical efficacy.…”

Section: Nanotechnology For Cell Crosstalk Regulationmentioning

confidence: 99%

Applications of nanotechnology in remodeling the tumour microenvironment for glioblastoma treatment

Mu,

Zhang,

Zhou

et al. 2024

Biomater. Sci.

View full text Add to dashboard Cite

show abstract

Nanomaterial‐Based Strategies for Preventing Tumor Metastasis by Interrupting the Metastatic Biological Processes

Cai,

He,

Zhou

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Tumor metastasis is the primary cause of cancer‐related deaths. The prevention of tumor metastasis has garnered notable interest and interrupting metastatic biological processes is considered a potential strategy for preventing tumor metastasis. The tumor microenvironment (TME), circulating tumor cells (CTCs), and pre‐metastatic niche (PMN) play crucial roles in metastatic biological processes. These processes can be interrupted using nanomaterials due to their excellent physicochemical properties. However, most studies have focused on only one aspect of tumor metastasis. Here, we highlight the hypothesis that nanomaterials can be used to target metastatic biological processes and explore strategies to prevent tumor metastasis. First, we briefly summarized the metastatic biological processes and strategies involving nanomaterials acting on the TME, CTCs, and PMN to prevent tumor metastasis. Further, we discussed the current challenges and prospects of nanomaterials in preventing tumor metastasis by interrupting metastatic biological processes. Nanomaterial‐and multifunctional nanomaterial‐based strategies for preventing tumor metastasis are advantageous for the long‐term fight against tumor metastasis and their continued exploration will facilitate rapid progress in the prevention, diagnosis, and treatment of tumor metastasis. We have outlined novel perspectives for developing more effective strategies to prevent tumor metastasis, thereby improving the outcomes of patients with cancer.This article is protected by copyright. All rights reserved

show abstract

Disturbed endothelial cell signaling in tumor progression and therapy resistance

Cited by 5 publications

References 58 publications

Biological mechanisms of resistance to immune checkpoint inhibitors and overcoming this resistance: Challenges in medical oncology

Biological mechanisms of resistance to immune checkpoint inhibitors and overcoming this resistance: Challenges in medical oncology

Applications of nanotechnology in remodeling the tumour microenvironment for glioblastoma treatment

Nanomaterial‐Based Strategies for Preventing Tumor Metastasis by Interrupting the Metastatic Biological Processes

Contact Info

Product

Resources

About